

## BRAIN

CCTG DISEASE SITE COMMITTEE MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON  
ROOM: CARLYLE

SATURDAY, APRIL 28, 2018, 9:00AM – 12:00 PM

CHAIRS : DR. WARREN MASON  
SENIOR INVESTIGATOR: DR CHRIS O'CALLAGHAN

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

1. To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to CNS malignancies
2. To summarize recent developments in molecular biology and therapeutics research, as related to CNS malignancies
3. To interpret and address, through clinical and translational research, the disease burden associated with CNS malignancies in Canada.
4. To interpret and apply new clinical trial methodologies in the field of clinical research in CNS malignancies

**9:00 am Welcome and Introductions**

**Actively Accruing Trials**

**9:05 am CEC.6 (NCCTG N0577):** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

**G.Cairncross**

**IND.222:** A phase I/II trial of AZD2014 with temozolomide in patients with GBM at first progression

**W.Mason**

**Newly Approved/Opened CCTG Trials**

**9:15 am CEC.5 (ALLIANCE 221208):** Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases

**C.Chung/W.Mason**

**CEC.3 (NCCTG N107C) \*closed\*:** A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease **D. Roberge**

**CE.7:** A Phase III Trial of Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases **D. Roberge**

**CE.8:** A phase III trial of the pan-proteasome inhibitor Marizomib with Radiotherapy and Temozolomide for newly-diagnosed GBM **W.Mason**

**10:15 – 10:45 am** **Coffee Break**

**Miscellaneous  
Strategic Plan – Direction of the Brain Committee**

**10:45 am** Introduction and Overview **W.Mason**

**11:00 am** CCSRI Grant review results **W.Mason**

**11:10 am** Key Speaker – Dr Gregory Cairncross:  
The State of Science in Brain Cancer **G.Cairncross**

**11:30 am** Summary of Strategic Planning Survey **W.Mason**

**11:40 am** Discussions